Profile data is unavailable for this security.
About the company
Hemogenyx Pharmaceuticals plc is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, and viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning for bone marrow transplantation (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HG-CT-1, is a CAR-T cell therapy designed to treat relapsed or refractory acute myeloid leukemia (R/R AML), which is in a Phase I clinical trial. Its Chimeric Bait Receptor (CBR) is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.
- Revenue in GBP (TTM)0.00
- Net income in GBP-7.81m
- Incorporated2013
- Employees16.00
- LocationHemogenyx Pharmaceuticals PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
- Websitehttps://hemogenyx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvonis Therapeutics PLC | 0.00 | -2.60m | 18.39m | -- | -- | 2.30 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -44.49 | -- | -54.32 | -- | -- | -- | -- | -- | -- | -645.25 | 0.011 | -- | -100.00 | -- | 53.62 | -- | -- | -- |
| Fusion Antibodies PLC | 1.60m | -1.47m | 19.07m | 24.00 | -- | 23.87 | -- | 11.95 | -0.0144 | -0.0144 | 0.0152 | 0.0064 | 0.9557 | 4.96 | 1.96 | 66,500.00 | -87.84 | -56.24 | -137.88 | -73.67 | 22.06 | 36.41 | -91.92 | -71.05 | 1.45 | -190.63 | 0.3483 | -- | 72.98 | -12.79 | 23.05 | -- | -37.98 | -- |
| Sareum Holdings Plc | 0.00 | -4.44m | 23.47m | 5.00 | -- | 10.04 | -- | -- | -0.0365 | -0.0365 | 0.00 | 0.0169 | 0.00 | -- | -- | 0.00 | -126.85 | -93.37 | -202.14 | -118.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.77 | -- | -- | -- |
| Arecor Therapeutics PLC | 5.06m | -8.10m | 28.70m | 37.00 | -- | 10.05 | -- | 5.67 | -0.2208 | -0.2208 | 0.1368 | 0.0756 | 0.6482 | 18.58 | 1.93 | 136,783.80 | -103.79 | -53.69 | -187.88 | -68.26 | -2.45 | -- | -160.13 | -248.39 | 2.00 | -- | 0.0571 | -- | 10.50 | -- | -19.66 | -- | -- | -- |
| Poolbeg Pharma PLC | 0.00 | -5.71m | 32.07m | 10.00 | -- | 2.69 | -- | -- | -0.0114 | -0.0114 | 0.00 | 0.0171 | 0.00 | -- | -- | 0.00 | -45.01 | -- | -46.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -47.29 | -- | -- | -- |
| ImmuPharma PLC | 0.00 | -3.93m | 32.38m | 6.00 | -- | 95.58 | -- | -- | -0.0089 | -0.0089 | 0.00 | 0.0007 | 0.00 | -- | -- | 0.00 | -139.44 | -89.81 | -259.88 | -121.17 | -- | -- | -- | -9,895.75 | -- | -2.76 | 0.00 | -- | -- | -- | 15.00 | -- | -56.60 | -- |
| hVIVO PLC | 51.28m | 5.28m | 48.78m | 301.00 | 9.23 | 1.12 | 5.45 | 0.9512 | 0.0077 | 0.0077 | 0.0748 | 0.0635 | 0.5914 | -- | 3.32 | 170,362.10 | 6.09 | 5.51 | 9.53 | 10.35 | -- | -- | 10.30 | 6.73 | 1.53 | -- | 0.2521 | 66.99 | 11.92 | 79.44 | -33.90 | -- | 154.59 | -- |
| Skinbiotherapeutics PLC | 4.64m | -696.25k | 51.13m | 41.00 | -- | 5.43 | -- | 11.02 | -0.0032 | -0.0032 | 0.0204 | 0.0364 | 0.5349 | 2.80 | 4.81 | 113,125.60 | -8.03 | -44.16 | -9.90 | -53.32 | 61.65 | -- | -15.01 | -175.65 | 4.29 | -12.21 | 0.0954 | -- | 283.74 | -- | 75.79 | -- | 16.61 | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -7.81m | 57.51m | 16.00 | -- | -- | -- | -- | -2.21 | -2.21 | 0.00 | -0.1089 | 0.00 | -- | -- | 0.00 | -169.60 | -87.04 | -210.76 | -102.48 | -- | -- | -- | -- | -- | -2.14 | 1.33 | -- | -- | -- | 16.01 | -- | 2.20 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.99m | 77.58m | 25.00 | -- | -- | -- | -- | -0.2526 | -0.2526 | 0.00 | -0.1354 | 0.00 | -- | -- | 0.00 | -119.80 | -227.46 | -304.25 | -1,738.54 | -- | -- | -- | -- | -- | -1.65 | 3.64 | -- | -- | -- | 16.24 | -- | 17.71 | -- |
| 4Basebio PLC | 1.78m | -14.41m | 91.68m | -- | -- | 4.82 | -- | 51.53 | -0.9923 | -0.9923 | 0.1226 | 1.23 | 0.0729 | 1.54 | 21.56 | -- | -59.05 | -36.81 | -64.81 | -40.98 | 61.55 | 69.88 | -809.95 | -1,160.83 | 11.15 | -95.30 | 0.4485 | -- | 84.39 | 35.80 | -60.90 | -- | 50.57 | -- |
| Bioventix PLC | 13.12m | 7.58m | 92.74m | 16.00 | 12.31 | 8.03 | 12.08 | 7.07 | 1.44 | 1.44 | 2.49 | 2.21 | 0.9864 | 1.84 | 2.10 | 819,741.90 | 57.04 | 58.17 | 64.40 | 64.19 | 90.86 | 92.79 | 57.83 | 61.84 | 8.65 | -- | 0.00 | 105.34 | -3.61 | 4.92 | -6.33 | 1.04 | -43.71 | 11.26 |
